145results about "Growth hormones" patented technology

The present invention relates to a method for the production and purification of a protein of interest, and more particularly, the present invention relates to a fusion protein comprising: a self-aggregating peptide, a linker peptide comprising an amino acid sequence selected from an elastin-like polypeptide (ELP) or a protease propeptide (ProP) and the spacer comprising a cleavage site, and a protein portion of interest, and a method for column-free one-step purification of a target protein by expressing the fusion protein.

The present invention proposes a growth hormone fusion protein and its application. The fusion protein includes an Fc mutant, which includes: a first peptide chain, wherein the first peptide chain 1) has a mutation at the following sites compared to the wild-type IgG4Fc fragment: at least one of the 234th, 235th, 298th, 299th, and 300th positions; or 231-239th positions; or 2) has a mutation at the following sites compared to the wild-type IgG1Fc fragment: at least one of the 228th-239th positions, and / or at least one of the 268th, 296th, 330th, and 331st positions. The fusion protein has a strong binding activity with human growth hormone receptors, can eliminate ADCC and CDC effects, promote Nb2-11 cell proliferation, and thus effectively treat or prevent diseases related to abnormal human growth hormone.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention discloses an aspergillus oryzae engineering bacterium as well as a construction method and application of the aspergillus oryzae engineering bacterium, and relates to the technical field of genetic engineering. The method comprises the following steps of: (a) connecting and fusing an open reading frame of an endogenous gene with a fungal laccase copper oxidoreductase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; or connecting and fusing an open reading frame of an endogenous gene with a multi-copper oxidase structural domain and a target heterologous protein gene through a dual-basic amino acid endopeptidase cleavage site gene; and (b) at least one of a gene Aovps10, a gene AosedD and a gene Aoemp47 is knocked out. The aspergillus oryzae engineering bacterium provided by the invention can realize high-efficiency expression of the heterologous protein, and the extracellular yield of the heterologous protein is obviously improved.

The invention provides a growth hormone fusion protein and application thereof. The fusion protein comprises an Fc mutant, the Fc mutant comprises an amino acid sequence as shown in SEQ ID NO: 49, or the Fc mutant comprises a first peptide chain and a second peptide chain, and the C end of the second peptide chain is connected with the N end of the first peptide chain; wherein a, compared with a wild type IgG4Fc fragment, the first peptide chain has the following mutations: F234V and L235E; or S298N, T299A, and Y300S, or a combination thereof; compared with a hinge region of wild type IgG4, the second peptide chain has S28P mutation; or b, compared with a wild type IgG4Fc fragment, the first peptide chain 1) has 231st-239th amino acid deletion; or (2) compared with a wild type IgG1Fc fragment, the IgG1Fc fragment has the following mutations: the 228th to 239th amino acid deletion, H268Q, Y296F, A330S and P331S. The fusion protein has high binding activity with a human growth hormone receptor, ADCC and CDC effects can be eliminated, Nb2-11 cell proliferation is promoted, and therefore human growth hormone abnormality related diseases are effectively treated or prevented.

The present application discloses compositions and methods for use of nucleoside modified mRNA that encode for at least one liver regenerative factor. The present invention also relates to compositions and methods for use of nucleoside modified mRNA complexed to nanoparticles. The disclosed compositions and methods are useful for treating acute liver diseases, chronic liver diseases, and / or acetaminophen (acetyl-para-aminophenol, APAP) overdose.

Described herein are growth hormone receptor antagonists and modified growth hormone receptor antagonists. The growth hormone receptor antagonists and modified growth hormone receptor antagonists are useful in treating diseases or conditions, such as cancer and acromegaly, that are responsive to human growth hormone receptor antagonists.

A peptide comprising the sequence shown below is added as a peptide tag to a useful protein, followed by allowing its expression.Xm(PYn)qPZr In this formula, X, Y, and Z each represent an amino acid residue independently selected from the group consisting of R, G, S, K, T, L, N, Q, and H, with the proviso that at least one Y represents K, L, N, Q, H, or R. m represents an integer of 0 to 5; n represents 1, 2, or 3; q represents an integer of 1 to 10; and r represents an integer of 0 to 10.

An unnatural amino acid, where the unnatural amino acid is a compound with a structure as shown in formula (I) or an enantiomer thereof,where X represents —O—, —S—, —NH— or —CH2—, Y represents —O—, —S—, —C(O)—, —S(O)— or —CH2—, and L represents substituted or unsubstituted C0-C20 linear or branched alkylene, where one or more —CH2— are optionally substituted by one or more of —O—, —S—, —NH—, —C(O)— and —S(O)—, when X represents —O— and Y represents —C(O)—, L does not represent —CH2CH2—, and when L represents a substituent, the substituent is selected from one or more of hydroxyl, sulfhydryl, halogen, nitro, cyano, alkyl, alkenyl, alkynyl, alkoxy, acyl, acylamino, carboxyl, ester, amino, sulfonyl, sulfinyl, cycloalkyl, heterocyclyl, aryl and heteroaryl.

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and / or prevention of diseases or disorders in which use of growth hormone is beneficial.

The present technology generally relates to peptides that bind to the growth hormone receptor (GhR), to peptides that bind to the GhR and have antagonistic activity, and to compositions comprising such peptides.

The invention provides an unnatural amino acid, which is a compound with a structure as shown in formula (I) or an enantiomer thereof. The invention further provides use of the unnatural amino acid. Furthermore, the invention further provides a recombinant protein containing the unnatural amino acid and a protein conjugate prepared from the recombinant protein. The unnatural amino acid provided by the invention is simple and convenient to prepare, safe in nature, not easy to be inactivated when being inserted into a protein, and has a high binding rate with a coupling moiety, and the obtained conjugate is higher in stability. The unnatural amino acid provided by the invention is applicable to numerous fields, especially in preparation of a recombinant protein or a recombinant protein conjugate,

The invention belongs to the technical field of biological medicines, and discloses a novel long-acting recombinant human growth hormone fusion protein. The fusion protein is obtained by fusion expression of human growth hormone (hGH) and an anti-human albumin nano antibody (VHH). And the long-acting principle is that the clearance rate is reduced by reversibly and widely combining with albumin with endogenous circulation. The fusion protein has the characteristics that 1, the fusion protein is obtained by fusion expression of two functional domains of hGH and VHH, hGH sequence mutation and complex chemical modification are not involved, the preparation method is simpler, and the sample uniformity is better; 2, in the fusion protein, the N end of the hGH protein has no additional structure, and the VHH functional domain is connected to the C end of the hGH, so that the influence on the activity of the hGH is reduced; and 3, animal efficacy results show that the fusion protein has a long-acting effect.

To provide pharmaceutical formulations for the treatment of diseases which can be treated with human growth hormone (hGH), and methods of the treatment, the formulations keeping the injection volume low to ensure administration of a drug in a manner convenient for a patient.SOLUTION: The present invention provides a polymeric human growth hormone prodrug, and a dry pharmaceutical formulation, a liquid pharmaceutical formulation and a reconstituted pharmaceutical formulation that comprise the prodrug. The present invention further provides the use thereof as medicaments for the treatment of diseases which can be treated with growth hormone, and methods of the treatment. The present invention also provides methods of application of such a polymeric human growth hormone prodrug or pharmaceutical formulation.SELECTED DRAWING: None

To provide nucleic acids (including AAV expression cassettes), AAV vectors, and compositions for use in methods of treating and / or delaying the onset of diseases associated with mutations in mecp2 genes, such as Rett Syndrome.SOLUTION: Also provided herein are methods for treating a brain-derived neurotrophic factor (BDNF) - associated disease and / or delaying the onset of a brain-derived neurotrophic factor (BDNF) - associated disease. The present disclosure provides a nucleic acid comprising an adeno-associated virus (AAV) expression cassette, wherein the AAV expression cassette comprises, in a 5' to 3' direction, a 5' inverted terminal repeat (ITR), a synthetic activity-dependent promoter, a Rett syndrome-associated gene, and a 3' ITR.SELECTED DRAWING: None

A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

Disclosed herein are antigenic peptide-MHC molecules, termed comPACTs, and methods of producing such molecules. Also disclosed herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells.

The present invention relates generally to peptides that bind to the growth hormone receptor (GhR), peptides that bind to the GhR and have antagonist activity, and compositions comprising such peptides.

The invention belongs to the technical field of biological medicines, and relates to a method for promoting synthesis and secretion of growth hormones by bovine gland pituitary cells, in particular to a method for promoting synthesis and secretion of growth hormones by melatonin. In-vitro experiments show that the melatonin can improve the level of adenosine cyclophosphate in cells, promote phosphorylation of PKA protein, promote expression of FOXO1 protein, combine the FOXO1 protein with a promoter of a Gh1 gene and promote synthesis and secretion of growth hormone by combining melatonin receptors in bovine pituitary cells. The application value of the melatonin in the fields of animal growth promotion, growth hormone deficiency treatment and the like is shown.

This disclosure provides engineered aminoacyl tRNA synthetases and tRNAs for efficient production of proteins containing non-standard amino acids. These engineered orthogonal tRNA (O-tRNA) / orthogonal aminoacyl tRNA synthetase (O-RS) pairs, i.e., Orthogonal Translation Systems (OTSs) can be used to incorporate a non-standard amino acid in a specific position in a growing polypeptide in response to a selector codon that is recognized by the engineered tRNA.

The present invention relates to a solid oral pharmaceutical composition comprising (i) a core comprising a peptide or protein drug, and (ii) a first coating, wherein the first coating comprises a copolymer (A) in combination with a copolymer (B) and / or a copolymer (C) and / or a copolymer (D).

The present invention relates to a solid oral pharmaceutical composition comprising (i) a core comprising a peptide or protein drug, and (ii) a first coating, wherein the first coating comprises a copolymer (A) in combination with a copolymer (B) and / or a copolymer (C) and / or a copolymer (D).

In one embodiment, the present invention provides an antibody specifically binding to human GH, or an antigen-binding fragment thereof. In one embodiment, the present invention pertains to an antibody specifically binding to human GH, or an antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein: the VH includes the amino acid sequence of SEQ ID NO: 5 as a VH complementarity determining region (CDR) 1 (VHCDR1), the amino acid sequence of SEQ ID NO: 6 as a VHCDR2, and the amino acid sequence of SEQ ID NO: 7 as a VHCDR3; and the VL includes the amino acid sequence of SEQ ID NO: 8 as a VL complementarity determining region (CDR) 1 (VLCDR1), the amino acid sequence of SEQ ID NO: 9 as a VLCDR2, and the amino acid sequence of SEQ ID NO: 10 as a VLCDR3.

The present invention relates to a heavy chain variable domain (V H ) and the light chain variable domain (V L The present invention provides engineered proteins of single-chain variable (scFv) fragments having an albumin-binding portion fused to the single-chain variable fragment, wherein the albumin-binding portion is connected by a linker.

The invention discloses a method for recombinant gene protein of sebastes schlegeli growth hormone, and belongs to the technical field of gene engineering. The sebastes schlegeli growth hormone gene is subjected to escherichia coli expression whole gene modification, and a label for 6Xhis purification is added; then, a recombinant escherichia coli (BL21 (DE3) / pET-28a) prokaryotic expression system is constructed, and sebastes schlegeli growth hormone fusion protein is expressed. The purified sebastes schlegeli growth hormone fusion protein is fed to fishes, and the average weight gain rate of the fishes is remarkably higher than that of a control group (Plt; 0.001), the average feed conversion ratio (FCR) is significantly reduced to 1.28 (Plt; the sebastes schlegeli growth hormone fusion protein prepared by the method provided by the invention has the advantages that the growth factor of the sebastes schlegeli growth hormone fusion protein is greatly improved, the feed utilization efficiency is obviously improved, the obtained sebastes schlegeli growth hormone fusion protein has a growth promoting effect, various risks caused by long breeding time are reduced, and the sebastes schlegeli growth hormone fusion protein shows a certain commercial application value.

The present invention relates to the fields of biotechnology and aquaculture, and in particular to a method for increasing the growth rate of fishes. The method comprises the following steps: fusing a coding region of a gh1 gene with a strong promoter of another endogenous highly-expressed gene in vivo, without introducing an exogenous gene, to generate a gh1 highly-expressed gene, wherein the strong promoter is a β-actin gene promoter. The present invention can create fast-growing fish species.

The present disclosure relates to methods, uses, compositions, and kits for using testosterones or testosterone derivatives and growth hormone (GH) or GH derivatives to improve muscle mass, muscle strength, or muscle function in a subject, or to reduce fatigue, pain, or obesity. One aspect of the present disclosure relates to combination therapies of testosterones or testosterone derivatives and GH or GH derivatives for treating various disorders associated with muscle wasting or conditions associated with muscle weakness.

The present disclosure provides an expression vector and a method for generating the expression vector. The expression vector includes one or more inserted foreign DNA sequences, including human growth hormone (hGH) and a plurality of therapeutic genes, where the one or more inserted foreign DNA sequences are fused with intracellular or extracellular secretion sequences; a promoter, configured to drive expression of the one or more inserted foreign DNA sequences; an insulator, configured for stable and safety expression of the one or more inserted foreign DNA sequences; a marker gene, configured to encoding one or more corresponding proteins to indicate the expression of the one or more inserted foreign DNA sequences; and a regulator element, configured to control expression of the hGH and the plurality of therapeutic genes under a controllable condition.